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Resistance genesA high proportion of methicillin-resistant Staphylococcus aureus isolates recovered in one year period showed
high-level mupirocin-resistance (HLMUPR-MRSA) in our environment (27.2%). HLMUPR-MRSA isolates were
mainly collected from skin and soft tissue samples, and diabetes was the main related comorbidity condition.
These isolates were more frequently found in vascular surgery. HLMUPR-MRSAwasmore resistant to aminogly-
cosides than mupirocin-susceptible MRSA, linked to the presence of bifunctional and/or nucleotidyltransferase
enzymes with/without macrolide resistance associated with the msr(A) gene. Most of HLMUPR-MRSA isolates
belonged to ST125/t067. Nine IS257-ileS2 amplification patterns (p3 was the most frequent) were observed in
HLMUPR-MRSA isolates, suggesting the presence of several mupirocin-resistance-carrying plasmids in our envi-
ronment and promoting the emergence of mupirocin resistance. The presence of the same IS257-ileS2 amplifica-
tion pattern p3 in 65% of HLMUPR-MRSA, all of them ST125/t067, suggests a clonal spread in our hospital and
community environment which could explain the high prevalence of HLMUPR-MRSA during the study period.
An outbreak situation or an increase in mupirocin consumption was not observed.om (C. Seral).© 2016 Elsevier Inc. All rights reserved.1. Introduction
Mupirocin, also known as pseudomonic acid A, is a topical antibiotic
that was originally isolated from Pseudomonas fluorescens. It is used for
decolonization of nasal carriers of methicillin-resistant Staphylococcus
aureus (MRSA) (Sutherland et al., 1985). The increased use of this anti-
biotic has been accompanied by outbreaks ofmupirocin-resistantMRSA
(Schmitz and Jones, 1997; Simor et al., 2007).
Mupirocin is an analogue of isoleucine that inhibits protein synthesis
by competitively binding to the enzyme isoleucyl-tRNA synthetase
(Yanagisawa et al., 1994). The high-level mupirocin-resistant isolates
show a MIC greater than 512 mg/L. This resistance is mediated by the
acquisition of a plasmid containing the ileS2 gene that encodes an
alternative isoleucyl-tRNA synthetase enzyme and is generally flanked
by copies of the insertion sequence IS257 (Pérez-Roth et al., 2010;
Woodford et al., 1998).The objective of the study was to identify the prevalence, clonal
lineages, resistance mechanisms and virulence genes of high-level
mupirocin-resistant MRSA (HLMUPR-MRSA) isolates recovered from
inpatients and outpatients in our institution during one year.
2. Material and methods
One hundred forty-sevenMRSA isolates were collected from clinical
samples in the University Teaching Hospital “Lozano Blesa” (Zaragoza,
Spain) from July 2009 to July 2010. Only one isolate per patient was in-
cluded. The study was conducted retrospectively. Clinical records of all
patients were reviewed. For each patient the following data were col-
lected: gender, age, medical service, source of the culture sample and
comorbid conditions during the year prior to MRSA isolation (dialysis,
diabetes, vascular disease, malignancy, hospitalization, MRSA isolation,
medical devices, contact with healthcare settings and surgery). To es-
tablish the possible community origin of MRSA isolates, CDC criteria
were followed, considering in this category the isolates from outpa-
tients with no hospitalization history during the last year, or from pa-
tients within their first 48 h after admission, who presented no other
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term care facility, dialysis, surgery, indwelling permanent catheters, or
medical devices. Antibiotic consumption in the year prior to isolation
was studied only in patients who carried HLMUPR-MRSA. Mupirocin
consumption data in our hospital were obtained frompharmacy records.
Identification and susceptibility testing was carried out byWIDER®I
System (Francisco Soria-Melguizo, Madrid, Spain) and disk diffusion
method and interpreted according to the CLSI guidelines (Clinical and
Laboratory Standards Institute (CLSI), 2014). High mupirocin MICs
(mupirocin MICs ≥ 256 mg/L) were confirmed by E-test strip method.
The main genes that encode resistance to macrolides, lincosamide,
streptogramin type B, aminoglycosides, tetracycline and mupirocin
were investigated by PCR (Aarestrup et al., 2000; Aktas et al., 2007;
Choi et al., 2003; Larsen et al., 2008; Lina et al., 1999; Udo et al., 2001).
Clinical strains usually harbor a complexmixture of resistance plasmids,
and laborious time consuming methodologies are required to associate
HLMUPR-MRSAwith a plasmid type (Leski et al., 1999; Pérez-Roth et al.,
2006). To enable the monitoring of HLMUP resistance dissemination in
staphylococci, we used a rapid typingmethod for strain characterization
based on the heterogeneous IS257-ileS2 spacer regions (amplification of
up- and down- stream IS257-ileS2 spacer regions) found on ileS2-
encoding plasmids. Four PCR reactions were performed, as previously
described (Pérez-Roth et al., 2011), on all mupirocin-resistant isolates.
All isolates were typed by spa typing (Larsen et al., 2008). Only
HLMUPR-MRSA isolates were typed by SCCmec, agr typing, PFGE using
SmaI and MLST as previously described (González-Domínguez et al.,
2012). PFGE profiles were analyzed with GelCompar II® software
(Applied Maths, Kortrijk, Belgium). Dendrograms were generated by
the unweighted pair-group method using arithmetic averages, based
on the Dice similarity coefficient with a 1.0% band position tolerance.
PFGE patterns were assigned into pulsotypes (named with capital
letters) and subtypes (named with numbers in subscript). Different
pulsotypes were considered if the similarity coefficient was b80%.
Different subtypes were considered when the similarity coefficient
oscillates in the 80–95% interval. HLMUPR-MRSA isolateswere screened
for virulence genes encoding Panton-Valentine leukocidin (PVL) (lukS-PV
and lukF-PV genes), exfoliative toxins ETA and ETB (eta and etb genes)
and toxic shock syndrome toxin (TSST) (tst gene) (Jarraud et al.,
2002; Larsen et al., 2008).
Statistical significance was calculated for comparison of proportions
using the chi-square test with Yates' correction. P ≤ 0.05was considered
statistically significant (SPSS V15.0; SPSS, Chicago, IL).3. Results and discussion
During the course of this study,MRSA prevalence in our hospitalwas
30.9%, consistent with other resistance rates found in different Spanish
hospitals (Cuevas et al., 2008; González-Domínguez et al., 2015; Lozano
et al., 2013). Forty MRSA isolates showed HLMUPR, representing 27.2%
of the studied isolates (mupirocin MICs ≥ 256 mg/L). This percentage
is higher than that found in other Spanish hospital (Daskalaki et al.,
2009). Other isolates were mupirocin-susceptible (i.e. MIC, b8 mg/L).
Mupirocin resistance appears to emerge easily in health centerswith
unrestricted policies that allow widespread use of mupirocin for long
periods (Lee et al., 2011). Between 2009 and 2010,mupirocin consump-
tion in our hospital stayed in approximately 1250 units per year (the
consumption in the community could not be established). This
mupirocin consumption has remained stable over the years. A guideline
for surveillance and control ofMRSA in hospitals was published in Spain
in 2008 (Rodríguez-Baño et al., 2008). Active surveillance cultures to
detect asymptomatic MRSA colonization is recommended in all guide-
lines for control and prevention of MRSA. In general, the guidelines rec-
ommends screening the patients at high risk of colonization (previously
colonized, patients withmultiple hospital or healthcare facilities admis-
sions with high prevalence of MRSA). In our hospital, mupirocin 2%nasal ointment is used for decolonization of nasal carriers of MRSA
after positive MRSA screening.
No statistically significant differences were found between patients with
HLMUPR-MRSA and mupirocin-susceptible MRSA isolates, regarding to age
(median: 75 years versus 72 years; P=0.124), male gender (50.0% versus
59.8%; P=0.285), community onset (25.0% versus 17.7%; P=0.326).
In relation to comorbidity conditions associated with patients in-
cluded in our study, diabetes was more frequently found in patients
with HLMUPR-MRSA than mupirocin-susceptible MRSA isolates
(35.0% versus 18.7%; P = 0.037); while the presence of malignancy
(10.0% versus 25.2%; P = 0.044) or medical devices (12.5% versus
30.8%; P= 0.024) were more related with patients who were infected
with mupirocin-susceptible MRSA isolates.
HLMUPR-MRSA were more frequently collected from skin and soft
tissue samples thanmupirocin-susceptible MRSA isolates (72.5% versus
27.1%; P b 0.001). This association between HLMUPR-MRSA and skin
and soft tissue infections has also been described by other authors
(Daskalaki et al., 2009). HLMUPR-MRSA was more frequently found in
vascular surgery service than mupirocin-susceptible MRSA (30.0%
versus 7.5%; P b 0.001). No significant differences in the prevalence of
othermedical serviceswere found. HLMUPR-MRSAwere less frequently
collected from lower respiratory tract samples than mupirocin-
susceptible MRSA isolates (2.5% versus 25.2%; P= 0.002).
During the year prior to isolation, the antibiotics most frequently
prescribed in patients who carried these HLMUPR-MRSA isolates were
beta-lactams (57.5%) and mupirocin (30%). These results were not
obtained in the group of mupirocin-susceptible MRSA isolates.
An aminoglycoside resistance phenotype was more frequently ob-
served among HLMUPR-MRSA than mupirocin-susceptible MRSA iso-
lates (gentamicin: 85.0% versus 11.2%; P b 0.001, kanamycin: 97.5%
versus 82.2%; P = 0.016, tobramycin: 92.5% versus 64.5%; P = 0.001,
amikacin: 85.0% versus 42.0%; P b 0.001, streptomycin: 12.5% versus
19.6%; P=0.314, netilmicin: 7.5% versus 0%; P=0.019) (Fig. 1). Amino-
glycoside resistance was encoded by aac(6′)-Ie-aph(2″)-Ia (85.0% ver-
sus 11.2%; P b 0.001) and ant(4′)-Ia (85.0% versus 64.5%; P = 0.016)
genes. A high rate of macrolide resistance was observed, but no signifi-
cant differences were found between high-level mupirocin-resistant
and mupirocin-susceptible isolates (erythromycin: 75.0% versus
58.8%; P = 0.07, azithromycin: 75.0% versus 58.8%; P = 0.07,
spiramycin: 17.5% versus 13.1%; P= 0.496, clindamycin: 17.5% versus
12.1%; P = 0.4). The difference in the prevalence of erythromycin
and clindamycin resistance is due to the high percentage of the
M phenotype that implicates erythromycin-resistant but clindamycin-
susceptible pattern. Macrolide resistance by efflux due to the
msr(A) gene is related with this phenotype. The main macrolide resis-
tance gene found in our HLMUPR-MRSA isolateswasmsr(A) (67.5% ver-
sus 43.9%; P = 0.011). None of HLMUPR-MRSA isolates showed
tetracycline resistance. Three predominant resistance gene profiles
were found in HLMUPR-MRSA isolates compared with mupirocin-
susceptible MRSA isolates. These profiles carried one or two aminogly-
coside resistance genes with or without the macrolide resistance
msr(A) gene. Profile 1: msr(A) + aac(6′)-Ie-aph(2″)-Ia + ant(4′)-Ia
(30.0% versus 0.9%; P b 0.001), Profile 2: aac(6′)-Ie-aph(2″)-Ia +
ant(4′)-Ia (25.0% versus 0%; P b 0.001) and Profile 3: msr(A) +
aac(6′)-Ie-aph(2″)-Ia + ant(4′)-Ia + aph(3′)-IIIa (12.5% versus 0%;
P = 0.001). However, mupirocin-susceptible MRSA isolates were
more related to isolates harboring the combination of msr(A) +
ant(4′)-Ia genes, only the ant(4′)-Ia gene or the susceptible phenotype.
All high-level resistant isolates carried the ileS2 gene. No association
between multidrug resistance and HLMUPR-MRSA were found as de-
scribed by Pérez-Roth et al., (Pérez-Roth et al., 2013). These isolates
showed higher gentamicin and tobramycin resistance rates than
mupirocin-susceptible MRSA isolates what could be related to the
aac(6′)-Ie-aph(2″)-Ia presence. This fact has been previously demon-
strated with the detection of the aac(6′)-Ie-aph(2″)-Ia and ileS2 genes












Fig. 1. Percentages of antibiotic resistance detected in high level mupirocin-resistant MRSA (HLMUPR-MRSA) and mupirocin-susceptible MRSA (MUPS-MRSA).
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observed among HLMUPR-MRSA isolates. The spa type t067 was the
predominant one (82%), although this spa type was also frequent inTable 1






ST spa type SCCmec agr Antibiotic resistance genes
p1 C 125 t067 IVc II msr(A) + erm(C) + aac(6
p2 A4 t2226 IVc II aac(6′)-Ie-aph(2″)-Ia + an
A5 t2226 IVc II aac(6′)-Ie-aph(2″)-Ia + an
A5 t2226 IVc II aac(6′)-Ie-aph(2″)-Ia + an
A6 t067 IVc II aac(6′)-Ie-aph(2″)-Ia + an
A10 t2226 IVc II msr(A) + aac(6′)-Ie-aph(2
p3 A2 t067 IVc II msr(A) + aac(6′)-Ie-aph(2
A3 t067 IVc II erm(C) + ant(4′)-Ia + ileS
A8 t067 IVc II msr(A) + aac(6′)-Ie-aph(2
A8 t067 IVc II msr(A) + erm(C) + aac(6
A9 t067 IVc II msr(A) + aac(6′)-Ie-aph(2
A9 t067 IVc II msr(A) + aac(6′)-Ie-aph(2
A9 t067 IVc II msr(A) + aac(6′)-Ie-aph(2
A9 t067 IVc II msr(A) + aac(6′)-Ie-aph(2
A9 t067 IVc II msr(A) + aac(6′)-Ie-aph(2
A9 t067 IVc II msr(A) + aac(6′)-Ie-aph(2
A9 t067 IVc II msr(A) + aac(6′)-Ie-aph(2
A9 t067 IVc II msr(A) + erm(C) + aac(6
A9 t067 IVc II msr(A) + erm(B) + aac(6
A9 t067 IVc II aac(6′)-Ie-aph(2″)-Ia + an
A10 t067 IVc II msr(A) + aac(6′)-Ie-aph(2
A11 t067 IVc II aac(6′)-Ie-aph(2″)-Ia + an
B1 t067 IVc II msr(A) + aac(6′)-Ie-aph(2
B1 t067 IVc II msr(A) + aac(6′)-Ie-aph(2
B2 t067 IVc II msr(A) + aac(6′)-Ie-aph(2
B2 t067 IVc II msr(A) + aac(6′)-Ie-aph(2
B3 t067 IVc II msr(A) + aac(6′)-Ie-aph(2
B4 t067 IVc II msr(A) + aac(6′)-Ie-aph(2
B4 t067 IVc II msr(A) + aac(6′)-Ie-aph(2
B4 t067 IVc II msr(A) + aac(6′)-Ie-aph(2
B6 t067 V II msr(A) + ant(4′)-Ia + ileS
C t067 IVc II msr(A) + erm(C) + aac(6
p4 A7 t067 IVc II erm(C) + ant(4′)-Ia + ileS
p5 B5 t067 IVc II aac(6′)-Ie-aph(2″)-Ia + an
p6 A11 t2220 IVc II msr(A) + aph(3′)-IIIa + il
A11 t2220 IVc II msr(A) + aph(3′)-IIIa + il
p7 B1 t067 IVc II aac(6′)-Ie-aph(2″)-Ia + an
p8 A1 5 t002 IVc II erm(C) + ileS2
p9 A6 125 t067 IVc II aac(6′)-Ie-aph(2″)-Ia + an
B1 t067 IVc II aac(6′)-Ie-aph(2″)-Ia + an
PFGE profile: Capital letters (A, B and C) mean strains with different PFGE profiles. The numbemupirocin-susceptible group (52%) where 22 different spa types were
found. spa type t067 is the most frequent spa type identified in Spain
(Argudín et al., 2009; González-Domínguez et al., 2012, 2015; LozanoDate of culture Onset
′)-Ie-aph(2″)-Ia + ant(4′)-Ia + ileS2 24/07/2009 Hospital
t(4′)-Ia + ileS2 28/07/2009 Hospital
t(4′)-Ia + ileS2 10/11/2009 Hospital
t(4′)-Ia + ileS2 24/12/2009 Hospital
t(4′)-Ia + ileS2 25/01/2010 Community
″)-Ia + ant(4′)-Ia + ileS2 26/09/2009 Hospital
″)-Ia + ant(4′)-Ia + ileS2 31/05/2010 Hospital
2 15/04/2010 Community
″)-Ia + ant(4′)-Ia + ileS2 29/07/2009 Hospital
′)-Ie-aph(2″)-Ia + ant(4′)-Ia + aph(3′)-IIIa + ileS2 30/07/2009 Hospital
″)-Ia + ant(4′)-Ia + ileS2 25/02/2010 Hospital
″)-Ia + ant(4′)-Ia + ileS2 13/04/2010 Hospital
″)-Ia + ant(4′)-Ia + ileS2 21/05/2010 Hospital
″)-Ia + ant(4′)-Ia + ileS2 10/06/2010 Hospital
″)-Ia + ant(4′)-Ia + ileS2 10/06/2010 Hospital
″)-Ia + ant(4′)-Ia + ileS2 23/06/2010 Hospital
″)-Ia + ant(4′)-Ia + aph(3′)-IIIa + ileS2 17/06/2010 Hospital
′)-Ie-aph(2″)-Ia + ant(4′)-Ia + aph(3′)-IIIa + ileS2 02/03/2010 Hospital
′)-Ie-aph(2″)-Ia + ant(4′)-Ia + aph(3′)-IIIa + ileS2 23/06/2010 Hospital
t(4′)-Ia + ileS2 28/06/2010 Hospital
″)-Ia + ant(4′)-Ia + ileS2 11/05/2010 Hospital
t(4′)-Ia + ileS2 23/06/2010 Hospital
″)-Ia + ant(4′)-Ia + aph(3′)-IIIa + ileS2 11/03/2010 Hospital
″)-Ia + aph(3′)-IIIa + ileS2 26/09/2009 Community
″)-Ia + ant(4′)-Ia + aph(3′)-IIIa + ileS2 20/05/2010 Hospital
″)-Ia + ant(4′)-Ia + aph(3′)-IIIa + ileS2 08/06/2010 Community
″)-Ia + ant(4′)-Ia + ileS2 31/05/2010 Hospital
″)-Ia + ileS2 05/07/2010 Hospital
″)-Ia + ant(4′)-Ia + ileS2 19/04/2010 Hospital
″)-Ia + ant(4′)-Ia + aph(3′)-IIIa + ileS2 21/04/2010 Hospital
2 03/11/2009 Community
′)-Ie-aph(2″)-Ia + ileS2 20/10/2009 Community
2 20/01/2010 Hospital
t(4′)-Ia + ileS2 03/05/2010 Hospital
eS2 22/06/2010 Hospital
eS2 25/01/2010 Community
t(4′)-Ia + ileS2 08/10/2009 Hospital
25/05/2010 Community
t(4′)-Ia + ileS2 31/05/2010 Community
t(4′)-Ia + ileS2 12/06/2010 Community
rs in subscript (1–11) indicate that those strains show closely related PFGE profiles.
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its high prevalence in both groups. Among the HLMUPR-MRSA strains,
97.5% of them belonged to ST125 and 2.5% to ST5. Both ST are included
in CC5, widely distributed in hospital and community settings in Spain
(Argudín et al., 2009; González-Domínguez et al., 2012, 2015; Lozano
et al., 2013). An association between MRSA CC5/ST125/t067 and eryth-
romycin resistance (encoded by msr(A)/msr(B) genes) has been
observed. This relation was previously described by other authors
(Daskalaki et al., 2009; González-Domínguez et al., 2015; Lozano et al.,
2013; Pérez-Roth et al., 2013). All HLMUPR-MRSA strains carried
SCCmec type IVc and agr type II, with the exception of one strain includ-
ed in SCCmec type V that belonged to ST125. None of the studied viru-
lence genes were identified among HLMUPR-MRSA isolates. Pulsed
field gel electrophoresis grouped the HLMUPR-MRSA strains in three
different PFGE pulsotypes (Table 1). The most prevalent was pulsotype
A that included 65% of the strains. This pulsotype had 11 subtypes
where subtype A9 was the most frequent. Thirty per cent of the strains
were included in pulsotype B, and subtype B1 was the most frequent.
Finally, 5% of strainswere included in pulsotype C. These results showed
that the strains were closely related.
Analyzing theHLMUPR-MRSA strains selected fromvascular surgery
we observed the presence of different clones (genetically unrelated).
Considering clinical, microbiological and molecular data, seventy-
five percent of HLMUPR-MRSA strains were classified as healthcare-
associated MRSA (HA-MRSA) clones (Table 1). The remaining
ones were community-onset MRSA (CO-MRSA) isolates related to HA-
MRSA clones (CO-HA-MRSA). HLMUPR-MRSA was not observed in
community-associated MRSA (CA-MRSA) clones.
In HLMUPR-MRSA isolates, distinct IS257-ileS2 spacer arrangements
(characterized by a different location of direct repeated copies of ileS2-
flanking IS257) allowed us to distinguish 9 IS257-ileS2 amplification
patterns, named p1 to p9. Transfer of ileS2-encoding plasmids is impor-
tant in the spread of HLMUPR-MRSA as evidenced by the recovery of
distinct plasmid configuration types in the same MRSA clone (Pérez-
Roth et al., 2013). We know that the IS257-ileS2 PCR might have
exceptional limitations (Pérez-Roth et al., 2006, 2010, 2011, 2013) but
we used this PCR as a first and simple approximation to address the
molecular epidemiology of plasmid-mediated HLMUPR-MRSA isolates
in our clinical setting. Only plasmid sequencing could definitely clarify
whether ileS2 plasmids are the same or not. The p3 pattern was the
most frequent in our hospital and community MRSA isolates (65%)
(Table 1). All of them belonged to the same clonal lineage ST125/t067
widely distributed in hospital and community settings in Spain. This
suggests a clonal spread in our environment which could explain the
high prevalence of HLMUPR-MRSA during the study period.
4. Conclusions
Most of HLMUPR-MRSA isolates that are circulating in our environ-
ment belonged to ST125/t067. This specific lineage is predominant in
our area and it is associated with resistance to aminoglycosides, and to
a lesser extent, tomacrolides. The presence of the same IS257-ileS2 am-
plification pattern p3 in 65% of HLMUPR-MRSA, all of them ST125/t067,
suggests a clonal spread in our hospital and community environment
which could explain the high prevalence of HLMUPR-MRSA during the
study period. An outbreak situation or an increase in mupirocin
consumption was not observed.
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